Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer
Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer
Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer
Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer
Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC
Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC
Selpercatinib benefit for advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer
Cost-benefit analysis of new cancer medicines: The difficult choices of governments
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer
OncoAlert Round Up for September 1-7, 2023
Part 6: Which different PARP inhibitors are available